BMY Latest Press Releases

-- December 11, 2025 --

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma Business Wire 6:59 AM

-- December 10, 2025 --

Bristol Myers Squibb Announces Dividend Increase Business Wire 4:16 PM

-- December 9, 2025 --

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer Globe Newswire 7:00 AM

-- December 8, 2025 --

Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025 Business Wire 4:30 PM

-- December 4, 2025 --

Bristol Myers Squibb's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL) Business Wire 8:15 PM

-- December 3, 2025 --

Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb Business Wire 11:00 AM

Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease Business Wire 6:59 AM

-- December 2, 2025 --

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now Globe Newswire 8:30 AM

-- December 1, 2025 --

Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio Business Wire 6:59 AM

-- November 26, 2025 --

Bristol Myers Squibb to Participate in Citi's 2025 Global Healthcare Conference Business Wire 6:59 AM

-- November 24, 2025 --

Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma Business Wire 5:00 PM

Bristol Myers Squibb to Host Hematology-Focused Investor Event Business Wire 6:59 AM

-- November 18, 2025 --

Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers Business Wire 2:25 PM

-- November 17, 2025 --

Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers Business Wire 10:33 PM

-- November 14, 2025 --

Update on Phase 3 Librexia ACS Trial Business Wire 6:59 AM

-- November 12, 2025 --

Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research Business Wire 9:00 AM

-- November 5, 2025 --

Bristol Myers Squibb Prices EUR 5 Billion of Senior Unsecured Notes Business Wire 2:47 PM

-- November 3, 2025 --

Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025 Business Wire 6:59 AM

Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes Business Wire 4:55 AM

-- October 30, 2025 --

Bristol Myers Squibb Reports Third Quarter Financial Results for 2025 Business Wire 6:59 AM

-- October 27, 2025 --

Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus Business Wire 6:59 AM

Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb ACCESS Newswire 2:50 AM

-- October 25, 2025 --

Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025 Business Wire 11:00 AM

-- October 17, 2025 --

SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025 PRNewswire 10:00 AM

-- October 14, 2025 --

insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro's ChemML Discovery Platform Business Wire 4:00 PM

-- October 13, 2025 --

Bristol Myers Squibb to Present Data at ESMO 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types Business Wire 6:59 AM

SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration PRNewswire 5:00 AM

-- October 10, 2025 --

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics Business Wire 6:59 AM

Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection Business Wire 6:45 AM

-- October 1, 2025 --

Bristol Myers Squibb's Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer's Disease Business Wire 6:59 AM

-- September 25, 2025 --

Bristol Myers Squibb Builds on Eliquis (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu (deucravacitinib) Business Wire 6:59 AM

-- September 23, 2025 --

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma Business Wire 6:59 AM

-- September 19, 2025 --

Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025 Business Wire 6:59 AM

-- September 17, 2025 --

Bristol Myers Squibb Announces Dividend Business Wire 6:59 AM

-- September 16, 2025 --

Bristol Myers Squibb to Participate in the Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Business Wire 6:59 AM

-- September 8, 2025 --

Stopping Cancer Before It Spreads: The EMT Revolution in Oncology Yolowire 3:43 PM

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity Globe Newswire 11:00 AM

Stopping Cancer Before It Spreads: The EMT Revolution in Oncology Yolowire 7:15 AM

-- August 29, 2025 --

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025 Business Wire 7:35 AM

Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference Business Wire 6:59 AM

-- August 25, 2025 --

Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025 Business Wire 6:59 AM

-- August 18, 2025 --

The Next Wave of Cancer Innovation: How Breakthrough Therapies Are Redefining Treatment Paradigms Yolowire 7:40 AM

Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer PRNewswire 6:00 AM

-- August 4, 2025 --

Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL) Business Wire 4:16 PM

-- July 31, 2025 --

Bristol Myers Squibb Reports Second Quarter Financial Results for 2025 Business Wire 6:59 AM

-- July 28, 2025 --

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients Business Wire 4:16 PM

-- July 25, 2025 --

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development Business Wire 6:59 AM

-- July 21, 2025 --

Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally Business Wire 6:59 AM

-- July 18, 2025 --

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia Business Wire 6:59 AM

-- July 17, 2025 --

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis (apixaban) Option Business Wire 6:59 AM